Viking Therapeutics enters September with nearly 20% of its free float sold short and options traders leaning more bullish than they have been in months — a split that makes the stock's positioning more nuanced than the headline short figure suggests.
Short interest is genuinely heavy. At 19.8% of free float, bears hold a significant structural position. The good news for shorts is that the borrow market isn't punishing them for it. Cost to borrow has eased back to 0.44% — low by any measure — after briefly touching 1.0% twice in August. Availability is running at roughly 204%, meaning about two shares are available to lend for every one already borrowed. That is a normal, well-supplied lending pool; there is no squeeze pressure building here. Short positions have also been slowly unwinding, down about 3.6% from a month ago and off the multi-week peak of 23.4 million shares seen in early August.
Options positioning tells a markedly different story to the shorts. The put/call ratio has dropped to 0.18 — the lowest reading of the past year, sitting close to the 52-week floor of 0.16, and running 1.5 standard deviations below its 20-day average. That is a heavily call-skewed options market. Traders are not hedging aggressively; they are reaching for upside. Whether that reflects genuine conviction in the pipeline or short-term speculative positioning is hard to distinguish from the data alone, but it is a stark contrast to a stock where one in five freely-traded shares is sold short.
The Street leans bullish but has been trimming ambitions. JP Morgan's Hardik Parikh cut his target from $75 to $65 on August 11, keeping an Overweight rating — a meaningful move from a bellwether firm, and one that pulled the consensus mean target down to roughly $92. That is still almost three times the current price of $33.67, which flags a consistency issue: either the consensus is stale relative to where the stock now trades, or there is an unusually wide dispersion in analyst views. Canaccord Genuity moved the other direction in late July, raising its Buy target to $114. The bull case centres on VK2735 — a single molecule across oral and injectable formats with multiple PBM partnership opportunities. The bear case is more structural: legal disputes with Ligand Pharmaceuticals, Phase 3 design hurdles requiring liver biopsies, and a crowded GLP-1 and metabolic-disorder competitive field. The ORTEX short score has crept to 74, a multi-week high, ranking in just the 8th percentile for short score among peers — meaning the aggregate short-positioning signal is elevated relative to most names in the universe.
The earnings calendar adds a concrete timing marker. Viking last reported on July 29, and the stock fell 2.2% the following day and ended the subsequent week roughly flat. The Q4 print is pencilled in for October 21. Between now and then, the stock has recovered 6% from a month ago and is off about 1.5% for the week, roughly in line with correlated peers — RLAY dropped 10% on the week, while MNPR gained 6%, illustrating the wide dispersion in small-cap biotech this week.
The dominant question heading into October is whether the clinical narrative — particularly any updates on VK2735's Phase 3 design or partnership discussions — can narrow the gap between where the stock trades and where analysts think it belongs. The persistence of nearly 20% short interest alongside deeply call-skewed options means any positive data catalyst would arrive into an already combustible positioning structure.
See the live data behind this article on ORTEX.
Open VKTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
